Recent Updates
Recently added Catalysts

DarioHealth Corp.

DRIOFDA catalysts, PDUFA dates & pipeline intelligence
$1.44
▼ -0.02 · -1.37%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full DRIO financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.0952W HIGH $14.77
Volume
90.91 K
Value Traded
146.24 K
Short % Float
1.35%
Days to Cover
1.2
-12.73%Week
-64.71%1 Month
-79.92%3 Month
-80.93%6 Month
-97.82%5 Year
-99.46%All Time

Cash Data

Unlock DRIO cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
16.25 M
EPS (TTM)
-3.02
P/E Ratio
-
Ent. Value
16.35 M
Total Shares
11.29 M
Float Shares
8.46 M
Insiders
25.07%
Institutions
15.11%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every DRIO catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

DRIO Catalyst Timeline

Dated clinical, regulatory and corporate events for DarioHealth Corp.

Unlock the full DRIO catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How DRIO actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all DRIO historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

DarioHealth Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every DRIO program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Dario Type 2 Diabetes2023-10-17hospital readmission reduction: 36%; hospital days reduction: 1.6; Hb A1c control improvement: 9%; poor control reduction: 13%Read MoreNew Research Shows 36% Reduction in 30-Day Hospital Readmission Rate for Dario Users with Type 2 DiabetesRead More
Scroll for more · summaries link to the source press release
Unlock every DRIO trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock DRIO insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Matheis DennisDirectorBuy 14,430 43,026 held$6.93 07/23/2026
Unlock the full DRIO insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 0 % 1.29 M 313.87 K -4.27% ( -14.00 K)
Unlock every fund holding DRIO
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in DRIO
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see DRIO ownership
Insider and institutional ownership, quarter by quarter.

DRIO Short Interest

Shares sold short, counted twice a month.

1.35%
Short % of Float
of tradable shares sold short
114.6K
Shares Sold Short
+41.1% vs prior count
1.2 Low
Days to Cover
trading days of normal volume to buy every short share back
95.1K
Avg Daily Volume
the average used for days to cover
Unlock DRIO short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock DRIO option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live DRIO option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock DRIO options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How DRIO ranks across every disease it competes in

Competitive Position is a premium feature
See how DRIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

DRIO News

DRIO
Nov 18, 2026
DRIOGeneral
▲ +27%on this news

Dario Secures Second Women's Health Contract in Just Weeks with The Minnesota Star Tribune

DarioHealth Corp. announced an expanded contract with The Minnesota Star Tribune to implement its Dario Women program, aimed at supporting women through perimenopause and menopause. This marks the second adoption of the program within weeks, reflecting strong demand for women's health solutions. The program will be available to eligible employees starting January 2027.

Read more →
DRIO
Nov 16, 2026
DRIOConferences/Events
▼ -8.7%on this newsshared move

Dario Presents New Research at ISPOR Europe 2026 Validating a Biometric-Driven Approach to Estimating Healthcare Cost Savings and ROI - Consistent with Published Benchmarks and Without Waiting for Claims Data

DarioHealth presented research at ISPOR Europe 2026 detailing a model to estimate cost savings from biometric improvements. The method translates changes in blood pressure and glucose into projected healthcare expenditure reductions. This approach allows purchasers to evaluate program value without waiting for delayed medical claims data.

Read more →
DRIO
Nov 12, 2026
DRIOGeneral
▼ -22.4%on this news· ran to -46% by day 3shared move

DarioHealth Reports Third Quarter 2026 Financial Results: Year-over-Year Revenue Growth and Operating Expense Reduction

DarioHealth reported a 6% year-over-year revenue growth for Q3 2026, reaching $5.3 million. The company also achieved a 15% reduction in operating loss and a stable gross margin of 59%. Dario anticipates further revenue acceleration driven by new enterprise customers and multi-condition expansions, including Dario Women™ and Dario Sleep.

Read more →
DRIO
Nov 4, 2026
DRIOGeneral

Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care

DarioHealth Corp. appointed John R. Palumbo as Chairman of the Board, effective November 3, 2026. This move aligns with the convergence of consumer and payer-led healthcare, as Dario aims to enhance chronic care management. Palumbo, with over 40 years of experience, will lead the Board in capturing strategic opportunities in this evolving market.

Read more →
DRIO
Nov 2, 2026
DRIOGeneral

DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026

DarioHealth Corp. will announce its financial results for Q3 2026 on November 12, 2026. The company will host a conference call at 8:30 a.m. Eastern Time, featuring key executives. DarioHealth focuses on AI-driven healthcare solutions to improve outcomes for chronic conditions.

Read more →
DRIO
Oct 26, 2026
DRIOGeneral
▼ -9.8%on this news

Dario Expands Contract with a Leading Regional Grocery Retailer, Adding Women's Digital Health and Clinical Care Program

DarioHealth Corp. announced a contract extension with a regional grocery retailer to include its Dario Women program, aimed at supporting women during perimenopause and menopause. This expansion follows the success of Dario's cardiometabolic program and reflects strong employee demand for women's health solutions. The program will launch in January 2027, enhancing Dario's multi-condition platform.

Read more →
DRIO
Oct 6, 2026
DRIOGeneral

DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs

DarioHealth Corp. announced the results of an independent review by Aon, which estimates a potential annual reduction in healthcare costs of 2.5% to 7.2% for users of its digital health platform. The analysis suggests significant savings for a typical 20,000-life population, amounting to $3.8 million to $10.8 million. Aon highlighted the platform's effectiveness in managing multiple chronic conditions and providing direct access to physicians, although the review had limitations regarding data verification.

Read more →
DRIO
Sep 17, 2026
DRIOGeneral

Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

DarioHealth Corp. announced a contract with a major New Jersey health plan, covering 1.5 million lives. This agreement, facilitated through Amwell, is set to launch in Q1 2027 and will enhance Dario's distribution strategy. It marks the third significant contract in the past year, expanding their reach in the healthcare market.

Read more →
DRIO
Aug 11, 2026
DRIOGeneral

DarioHealth Reports Second Quarter 2026 Financial Results

DarioHealth Corp. reported its second quarter 2026 financial results, showing a revenue of $5.2 million, a decrease from the previous quarter. The company achieved a gross margin of 62%, up from 57% in Q1 2026, and reduced its operating loss by 30% year-over-year. DarioHealth is expanding its multi-condition platform and has secured significant new clients, enhancing its revenue potential.

Read more →
DRIO
Aug 4, 2026
DRIOGeneral

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

DarioHealth Corp. announced the launch of Dario Women™ and Dario Sleep™, expanding its cardiometabolic platform. These new programs aim to improve health outcomes through AI-driven engagement and provider-backed care. Revenue from these initiatives is expected to begin in Q4 2026, addressing significant clinical needs for employers and health plans.

Read more →
DRIO
Aug 3, 2026
DRIOConferences/Events

DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026

DarioHealth Corp. will announce its financial results for Q2 2026 on August 11, 2026. The company, known for its AI-driven healthcare solutions, will host a conference call at 8:30 a.m. ET, featuring key executives. This event aims to provide insights into the company's performance and future strategies.

Read more →
DRIO
Jul 30, 2026
DRIOGeneral

Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience

DarioHealth has launched its Integrated GLP-1 Program, combining digital chronic care with provider-backed clinical services. This initiative aims to meet the needs of consumers seeking GLP-1 therapies amid changing reimbursement models. The program will be available through various channels starting in Fall 2026, with anticipated revenue growth into 2027.

Read more →
DRIO
Jul 22, 2026
DRIOGeneral
▲ +12.9%on this news

Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

DarioHealth Corp. has announced a registered direct offering of common stock, raising approximately $23.5 million. The offering, priced at $6.80 per share, involves participation from existing long-term investors and new institutional investors. The funds will be utilized for working capital, investments, and general corporate purposes, with the closing expected on July 23, 2026.

Read more →
DRIO
Jul 16, 2026
DRIOGeneral

Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform

DarioHealth Corp. announced a contract with a Fortune 50 employer to provide its AI-powered cardiometabolic care platform for over 100,000 employees. The program, launching in Fall 2026, aims to improve health outcomes and reduce costs associated with chronic conditions like diabetes and hypertension. Revenue is expected to begin by the end of 2026 and increase through 2027.

Read more →
DRIO
Jul 13, 2026
DRIOGeneral
▼ -7.2%on this newsshared move

Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%

DarioHealth Corp. expects its AI platform, DarioIQ, to boost annual B2B2C recurring revenue by 10-15% from existing customers. The platform enhances member engagement by 40% and retention by 20%, leveraging over 13 billion healthcare data points. The company aims to improve clinical outcomes and ROI while expanding its market presence.

Read more →
DRIO
Jul 6, 2026
DRIOGeneral

Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership

DarioHealth Corp. has signed a new agreement with a major health insurer in Arizona through its partnership with Amwell. This agreement allows Dario's cardiometabolic digital health solutions to be offered to a large population of self-insured employers. The initiative aims to reduce cardiometabolic risks and costs while providing tailored health solutions to meet specific employer needs.

Read more →
DRIO
Jul 2, 2026
DRIOGeneral
▲ +7.9%on this newsshared move

Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy

DarioHealth Corp. has expanded its partnership with a major U.S. health insurer, adding hypertension solutions to its existing behavioral health offerings. This extension is expected to triple revenue opportunities under this customer relationship, reinforcing Dario's multi-condition care strategy. The company aims to improve health outcomes while reducing costs through integrated care solutions.

Read more →
DRIO
Jun 30, 2026
DRIOGeneral

Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships

DarioHealth Corp. has appointed Sean O'Reilly, former Chief Compliance Officer at Humana, to its Advisory Board. His extensive experience in healthcare compliance and risk management is expected to support Dario's growth strategy and enhance its relationships with health plans, employers, and providers. O'Reilly's background in leveraging AI for value-based care aligns with Dario's mission to improve healthcare outcomes.

Read more →
DRIO
Jun 29, 2026
DRIOGeneral

Dario Announces Strategic Collaboration with Beluga Health to Deliver Provider-Backed, Integrated Care at Scale

DarioHealth Corp. has announced a strategic collaboration with Beluga Health to enhance its digital health solutions. This partnership aims to provide a provider-backed, integrated care model that combines Dario's chronic care platform with Beluga's clinical network. The collaboration is expected to improve member engagement, lower healthcare costs, and expand into new markets, positioning Dario as a key player in value-based care.

Read more →
DRIO
Jun 8, 2026
DRIOConferences/Events

Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform

DarioHealth Corp. presented notable findings at the American Diabetes Association Scientific Sessions, showcasing the effectiveness of its digital health platform in managing chronic conditions like diabetes and obesity. The studies highlighted that sustained engagement with the platform leads to improved clinical outcomes, as evidenced by significant weight loss and reductions in hospitalizations among high-risk patients. Findings indicate potential cost savings for payers and a compelling case for enterprise buyers to adopt integrated solutions for better patient management across multiple chronic conditions. With a total of 27 studies presented over eight years, Dario reinforces its strategic move towards value-based healthcare.

Read more →

About DarioHealth Corp.

New York, NY 165 employees mydario.com
Headquarters322 W 57TH ST. #33B, NEW YORK, NY, 10019
BIOPHARMAWATCH ELITE
Trade the next DRIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime